Table 3.
Selected Clinical Trials of VEGF-targeted therapy in combination with immune checkpoint inhibitors (July 2017).
| Anti-angiogenic | Immunotherapy | Phase | Indications | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Bevacizumab | Ipilimumab | 2 | Melanoma | NCT01950390 |
| Bevacizumab | Ipilimumab | 1 | Melanoma | NCT00790010 |
| Bevacizumab | Atezolizumab | 2 | CRC | NCT02982694 |
| Bevacizumab | Atezolizumab | 2 | Melanoma brain metastases | NCT03175432 |
| Bevacizumab | Atezolizumab | 2 | RCC | NCT02724878 |
| Bevacizumab | Atezolizumab | 3 | RCC | NCT02420821 |
| Bevacizumab | Nivolumab | 2 | Ovarian, Fallopian Tube Or Peritoneal Cancer | NCT02873962 |
| Bevacizumab | Nivolumab | 3 | Glioblastoma | NCT02017717 |
| Bevacizumab | Nivolumab | 1 | NSCLC | NCT01454102 |
| Bevacizumab | Nivolumab | 1 | RCC | NCT02210117 |
| Bevacizumab | Pembrolizumab | 2 | RCC | NCT02348008 |
| Bevacizumab | Pembrolizumab | 1/2 | NSCLC | NCT02039674 |
| Bevacizumab | Pembrolizumab | 2 | Glioblastoma | NCT02337491 |
| Bevacizumab | Pembrolizumab | 2 | Melanoma/NSCLC brain metastases | NCT02681549 |
| Aflibercept | Pembrolizumab | 1 | Solid tumors | NCT02298959 |
| Sunitinib | Nivolumab | 1 | RCC | NCT01472081 |
| Axitinib | Pembrolizumab | 3 | RCC | NCT02853331 |
| Axitinib | Avelumab | 3 | RCC | NCT02684006 |
| Cabozantinib | Nivolumab | 3 | RCC | NCT03141177 |
CRC, colorectal cancer; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.
For reference see https://clinicaltrials.gov.